PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
基本信息
- 批准号:2003899
- 负责人:
- 金额:$ 12.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-01-01 至 1998-12-31
- 项目状态:已结题
- 来源:
- 关键词:MHC class I antigen antigen presentation cytotoxic T lymphocyte enzyme complex gene expression gene mutation genetic polymorphism high performance liquid chromatography immunogenetics immunoregulation intracellular laboratory mouse molecular cloning nucleic acid sequence ovalbumin peptide structure proteasome protein purification proteolysis tissue /cell culture
项目摘要
Cells of higher vertebrates have evolved mechanisms enabling them to
display on their surfaces a sampling of their intracellular contents, in
the form of peptides bound to major histocompatibility complex (MHC)
class I molecules. Such complexes. are required not only for the
recognition and destruction of cells harboring intracellular pathogens,
or cells containing altered forms of self proteins, such as oncogenes,
but also for the positive and negative selection of T cells during their
development in the thymus. It is therefore important to determine how
these peptide-MHC complexes are generated. Moreover, recent data suggest
that not all peptides of a given antigen which can bind to a particular
MHC class I molecule are in fact produced under normal circumstances, and
that polymorphism in antigen processing may alter the repertoire of
peptides presented to T cells in different individuals. Thus, it is
important to determine whether and to what extent the specificity of, and
potential polymorphism in, their generation affects the repertoire of
peptides that are presented to T cells.
Despite their critical importance, the mechanisms by which peptides
relevant to presentation to T cells are produced in normal cells are
currently unknown. However, recent evidence implicates a large
intracellular structure called the LMP complex in this process. Although
the circumstantial evidence is strong, no direct proof for this function
yet exists. The experiments described in this proposal are designed to
test this hypothesis both genetically and functionally. Specifically, we
will determine whether LMP complex genes are required for normal antigen
processing, and whether purified LMP complex is capable of producing
relevant peptides in vitro. Furthermore, the effect of the known
(allelic) structural variation in this complex on its proteolytic
activity and/or specificity will be determined. We will also expand on
the preliminary indications that different forms of the complex exist in
different tissues, and test the potential relationship of this structural
variation to function. The results of these studies may have important
implications for individual differences in immune responsiveness, the
genetic basis of MHC-linked predisposition to disease, and MHC-class I
matched and non-matched transplantation.
高等脊椎动物的细胞已经进化出一种机制,使它们能够
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Physical and functional association of the major histocompatibility complex class I heavy chain alpha3 domain with the transporter associated with antigen processing.
主要组织相容性复合体 I 类重链 α3 结构域与抗原加工相关转运蛋白的物理和功能关联。
- DOI:10.1084/jem.187.6.865
- 发表时间:1998
- 期刊:
- 影响因子:0
- 作者:Kulig,K;Nandi,D;Bacik,I;Monaco,JJ;Vukmanović,S
- 通讯作者:Vukmanović,S
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John J. Monaco其他文献
Genomic polymorphism, recombination, and linkage disequilibrium in human major histocompatibility complex-encoded antigen-processing genes.
人类主要组织相容性复合体编码的抗原加工基因的基因组多态性、重组和连锁不平衡。
- DOI:
10.1073/pnas.89.23.11594 - 发表时间:
1992 - 期刊:
- 影响因子:11.1
- 作者:
P. M. V. Endert;M. T. Lopez;S. Patel;John J. Monaco;H. Mcdevitt - 通讯作者:
H. Mcdevitt
MHC class II region encoding proteins related to the muKidrug resistance family of transmembrane transporters
MHC Ⅱ类区域编码与跨膜转运蛋白 muKidrug 耐药家族相关的蛋白质
- DOI:
10.1038/348738a0 - 发表时间:
1990-12-27 - 期刊:
- 影响因子:48.500
- 作者:
Edward V. Deverson;Irene R. Gow;W. John Coadwell;John J. Monaco;Geoffrey W. Butcher;Jonathan C. Howard - 通讯作者:
Jonathan C. Howard
New class ll-like genes in the murine MHC
小鼠主要组织相容性复合体中的新型类 II 基因
- DOI:
10.1038/353573a0 - 发表时间:
1991-10-10 - 期刊:
- 影响因子:48.500
- 作者:
Sungae Cho;Michelle Attaya;John J. Monaco - 通讯作者:
John J. Monaco
Production of congenic Anti-Lyt-3.1 sera
- DOI:
10.1007/bf01844002 - 发表时间:
1978-12-01 - 期刊:
- 影响因子:2.900
- 作者:
Stephen C. Boos;John J. Monaco;Paul D. Gottlieb - 通讯作者:
Paul D. Gottlieb
John J. Monaco的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John J. Monaco', 18)}}的其他基金
Proteasome subunit beta5t and thymus-specific peptides in T cell selection
T 细胞选择中的蛋白酶体亚基 beta5t 和胸腺特异性肽
- 批准号:
8701462 - 财政年份:2014
- 资助金额:
$ 12.75万 - 项目类别:
Proteasome subunit beta5t and thymus-specific peptides in T cell selection
T 细胞选择中的蛋白酶体亚基 beta5t 和胸腺特异性肽
- 批准号:
8824482 - 财政年份:2014
- 资助金额:
$ 12.75万 - 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
- 批准号:
2068671 - 财政年份:1993
- 资助金额:
$ 12.75万 - 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
- 批准号:
2068673 - 财政年份:1993
- 资助金额:
$ 12.75万 - 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
- 批准号:
2068672 - 财政年份:1993
- 资助金额:
$ 12.75万 - 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
- 批准号:
3148678 - 财政年份:1993
- 资助金额:
$ 12.75万 - 项目类别:
ROLE OF THE PROTEASOME/LMP COMPLEX IN ANTIGEN PROCESSING
蛋白酶体/LMP 复合物在抗原加工中的作用
- 批准号:
3148679 - 财政年份:1993
- 资助金额:
$ 12.75万 - 项目类别:
MHC GENES INVOLVED IN ANTIGEN PROCESSING & PRESENTATION
参与抗原加工的 MHC 基因
- 批准号:
3147889 - 财政年份:1992
- 资助金额:
$ 12.75万 - 项目类别:
MHC GENES INVOLVED IN ANTIGEN PROCESSING & PRESENTATION
参与抗原加工的 MHC 基因
- 批准号:
2067654 - 财政年份:1992
- 资助金额:
$ 12.75万 - 项目类别:
MHC GENES INVOLVED IN ANTIGEN PROCESSING & PRESENTATION
参与抗原加工的 MHC 基因
- 批准号:
3147888 - 财政年份:1992
- 资助金额:
$ 12.75万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 12.75万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 12.75万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 12.75万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 12.75万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 12.75万 - 项目类别: